If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Subscribe To Our Newsletter & Stay Updated
